Retrospective study on the health and economic burden of hospitalized patients due to pneumonia and invasive pneumococcal infections in Belgium settings

Vaccine. 2024 Apr 30;42(12):3018-3023. doi: 10.1016/j.vaccine.2024.03.057. Epub 2024 Apr 4.

Abstract

Introduction: pneumococcal infections are associated with high morbidity, hospitalisation and mortality. The objective of this study was to investigate the health and economic burden of all-cause pneumonia and invasive pneumococcal disease in Belgian hospital settings, by patient's age and risk profile.

Methods: This descriptive retrospective study was conducted in 17 Belgian hospitals. Univariate and multivariate logistic linear regression models were performed. The Health Insurance and patient's cost perspectives were considered because a few studies report these costs.

Results: The analysis has included 4,712 hospital admissions over the year 2018. Median hospitalization costs were higher for invasive pneumococcal infection diagnosis than for all-cause pneumonia (p < 0,001), respectively 4,051€ and 3,362€. Other factors associated with higher hospitalization cost were patient's high-risk profile, admission to emergency unit, transfer from nursing home, admission to intensive care unit and length of stay.

Conclusion: Streptococcus pneumoniae infections remain a public health problem with significant cost for the Health Insurance and poor prognosis. Invasive pneumococcal infections are associated with longer hospital stays and required more intensive care than all other causes of pneumonia, in addition to be more costly, which justifies more attention for vaccination. This study also suggests an increase of economic and health burden with age and presence of underlying conditions.

Keywords: Belgian settings; Community acquired pneumonia; Health and economic burden; Hospitalization cost and length of stay; Invasive pneumococcal infection; Mortality.

MeSH terms

  • Belgium / epidemiology
  • Community-Acquired Infections*
  • Financial Stress
  • Hospitalization
  • Humans
  • Pneumococcal Infections* / epidemiology
  • Pneumococcal Vaccines / therapeutic use
  • Pneumonia*
  • Pneumonia, Pneumococcal* / epidemiology
  • Retrospective Studies

Substances

  • Pneumococcal Vaccines